Alembic Pharmaceuticals has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 54.64% rise in its net profit at Rs 201.87 crore for the quarter under review as compared to Rs 130.54 crore for the same quarter in the previous year. Total income of the company increased by 13.19% at Rs 1,481.78 crore for Q4FY24 as compared Rs 1,309.08 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 16.78% rise in its net profit at Rs 178.21 crore for fourth quarter ended March 31, 2024 as compared to Rs 152.60 crore for the same quarter in the previous year. Total income of the company increased by 8.05% at Rs 1,520.57 crore for Q4FY24 as compared Rs 1,407.34 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 92.22% rise in net profit at Rs 666.48 crore as compared to Rs 346.73 crore for the previous year. Total income of the company increased by 14.61% at Rs 5,905.38 crore for year under review as compared to Rs 5,152.54 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 80.07% rise in its net profit at Rs 615.82 crore as compared to Rs 341.99 crore for the previous year. Total income of the company increased by 10.64% at Rs 6,256.93 crore for year under review as compared to Rs 5,655.36 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |